ChAdOx1 nCoV-19 Vaccine - PrecisionVaccinations

ChAdOx1 nCoV-19 Vaccine Description

The ChAdOx1 nCoV-19 vaccine candidate consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the genetic sequence of the SARS-CoV-2 Spike protein.

After vaccination, the surface spike protein of the specific coronavirus is produced, which primes the immune system to attack the coronavirus if it later infects the body.

ChAdOx1 nCoV-19 Vaccine Indication

The ChAdOx1 nCoV-19 vaccine candidate is being tested in clinical trials to prevent infection of SARS-CoV-2 which causes COVID-19 disease.

ChAdOx1 nCoV-2 Vaccine Clinical Trial

Clinical Trial NCT04324606: A phase I single-blinded, randomized, placebo-controlled, multi-center study to determine efficacy, safety, and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years. Primary outcomes: Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases [ Time Frame: 6 months ]. The number of virologically confirmed (PCR positive) symptomatic cases of COVID-19. Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs) [ Time Frame: 6 months ]. The occurrence of serious adverse events (SAEs) throughout the study duration.

ChAdOx1 nCoV-2 Vaccine News

• April 30, 2020 - On April 30, 3030, AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the recombinant adenovirus vaccine aimed at preventing COVID-19 disease from SARS-CoV-2 coronavirus infections.
• April 28, 2020 - The Serum Institute of India said it plans to produce up to 60 million doses of the vaccine against the new coronavirus that is under clinical trial in Britain.
• April 24, 2020 - Vaccitech announces today that its scientific founders at the Jenner Institute, University of Oxford, have begun testing a COVID-19 vaccine in human volunteers.
• April 23, 2020 - University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine, and the control group receiving a widely available meningitis vaccine. 

CONTENT SOURCES:  World Health Organization, US Centers for Disease Control and Prevention, clinicalTrials.gov, and the Precision Vaccinations news network.